The Pharmaceutical Journal Vol 267 No 7173 p667-671
10 November 2001

This article
Reprint
Photocopy

News summary

NICE guidance on MS

The National Institute for Clinical Excellence (NICE) published the final consultation document of its appraisal on beta-interferon and glatiramer acetate for multiple sclerosis (MS) on 2 November. It concludes that neither treatment should be recommended for the treatment of MS through the National Health Service.

See also News feature

Back to Top